abstract: Altered lipid metabolism is associated with human abnormal pregnancy, such as pre-eclampsia and preterm labor, and potentially leads to fetus loss. A causative factor for the onset and progress of the systemic multifactorial syndromes associated with the pathological pregnancy is oxidized low-density lipoprotein, an active identity of which was postulated to be lysophosphatidic acid (LPA). We previously found that LPA is produced extracellularly by plasma lysophospholipase D (lysoPLD) activity of autotaxin, a tumor cell motility-stimulating protein. In this study, a convenient assay based on the choline released from endogenous substrate or exogenous lysophosphatidylcholine (LPC) was used for comparison of serum lysoPLD activity among patients with normal and abnormal pregnancy. The serum choline-producing activity was found to be mainly due to autotaxin, and dependent on its dilution rate. There was some association between low dilution dependency of serum lysoPLD activity toward an exogenous LPC and high lysoPLD activity toward endogenous substrates in cases of patients with preterm labor and pre-eclampsia. However, there was no difference in the serum level of LPC between women with normal pregnancy and those with pathological pregnancy. These results indicate that production of bioactive LPA by lysoPLD activity is elevated by an unknown mechanism that may be related to increased availability of endogenous substrates LPC, but not its concentration in human serum. If the level of LPA in blood circulation is elevated in the pathological pregnancies in vivo, it may play a role in induction and/or progression of systemic vascular dysfunction seen patients with preterm labor or pre-eclampsia.
Introduction
Altered lipid metabolism is associated with human pregnancy that potentially leads to fetus loss. Pre-eclampsia is such a disease with hypertension, renal edema, proteinuria and activated blood coagulation (Dekker and Sibai, 1998) . Another type of abnormal pregnancy is preterm labor that may lead to preterm parturition. Bacterial infection is the main basis in the etiology of human preterm labor (Goldenberg et al., 2008) . Although its mechanism is still a matter of debate, a molecular basis for the etiology of pre-eclampsia is excess accumulation of atherogenic lipids that may induce vascular endothelial dysfunction, leading to atherosclerosis (Coffey, 2003) . Abnormal lipid profiles, such as hypertriglyceridemia (Llurba et al., 2005) , predominance of small, dense low-density lipoprotein (Llurba et al., 2005) and oxidative modification of lipoproteins (Branch et al., 1994; Takacs et al., 2001) , in plasma from pre-eclamptic patients, have also been postulated as causative factors for the onset and progress of this systemic multifactorial syndrome. As an active identity of the atherogenic lipoproteins in the etiology of pre-eclampsia, lysophosphatidic acid (1-or 2-radyl-sn-glycerol 3-phosphate, LPA) is of particular interest, because this lysophospholipid mediator was reported to induce acute atherogenesis in a rat model when experimentally retained into an common carotid artery followed by balloon injury of the carotid artery in vivo (Yoshida et al., 2003) , and because more LPA is present in oxidized LDL than in native LDL (Zhang et al., 2004) .
LPA is an important lysophospholipid mediator that exerts diverse physiological activities by interacting with its specific G-protein-coupled receptors (Hecht et al., 1996; Bandoh et al., 1999; Goetzl et al., 1999; Noguchi et al., 2003; Kotarsky et al., 2006; Lee et al., 2006; Tabata et al., 2007) . A key enzymatic activity for extracellular production of LPA, lysophospholipase D (lysoPLD)-like activity, was first detected in rat plasma (Tokumura et al., 1986) . Similar lysoPLD-like activities in human plasma (Tokumura et al., 2002a) and fetal calf serum (Umezu-Goto et al., 2002) were later purified and characterized as a secretory form of autotaxin (ATX), a member of ecto-nucleotide pyrophosphatase/phosphodiesterase (ENPP-2) that was originally isolated as a tumor cell-motility stimulating protein in culture medium of human melanoma cells (Stracke et al., 1992; Bollen et al., 2000) . The ATX/lysoPLD was then demonstrated to be a key enzyme that determines the level of LPA in blood plasma, since the plasma level of LPA in ATX 2/2 mice was nearly half that of normal mice (Tanaka et al., 2006; Van Meeteren et al., 2006) . Our group reported that LPA plays roles in female reproductive system as follows: stimulated maturation of mouse (Komatsu et al., 2006) and hamster (Hinokio et al., 2002) oocytes, stimulated preimplantation development of mouse embryos (Kobayashi et al., 1994) and accelerated transport of mouse ovum in the oviducts (Kunikata et al., 1999) . Others reported that LPA accelerates blastocyst outgrowth (Shiokawa et al., 2000; Liu and Armant, 2004) . Furthermore, deletion of an LPA receptor (LPA 3 ) in mice led to increased embryonic death, which is caused by embryo crowding and delayed embryo implantation (Ye et al., 2005) , and LPA/LPA 3 was later shown to regulate both events independently (Hama et al., 2007) . Additionally, LPA was found to be present in human follicular fluid and uterine flushings of domestic mammals (Seo et al., 2008; Liszewska et al., 2009 ) at micromolar concentrations. We previously reported that the production of LPA by lysoPLD activity in serum is considerably increased during human pregnancy (Tokumura et al., 2002b) , indicating the physiological role of LPA production by lysoPLD in blood circulation on maintenance of pregnancy (Tokumura, 2002; Tokumura et al., 2002b) . In addition, we found that the average lysoPLD activity in serum from patients suffering from preterm labor, toward exogenous lysophosphatidylcholine (LPC) having an sn-1-palimitoyl (16:0), but not linoleoyl (18:2) group, was significantly higher than in serum from women suffering from no symptoms of pathological pregnancy. This finding allowed us to speculate that elevated LPA production in blood circulation under pathological pregnancy might be relevant to inducing systemic symptoms of preterm labor, since that LPA was identified as a vasopressor in the rat (Tokumura et al., 1978) and since that LPA was reported to induce aggregation of human and feline platelets in vivo and in vitro (Schumacher et al., 1979; Tokumura et al., 1981) . Relative availabilities of exogenous LPCs for plasma lysoPLD might be affected by some plasma components such as plasma proteins, lipids and bivalent ions. In this context, relative availability of endogenous LPCs for ATX/lysoPLD in plasma from patients with abnormal pregnancy would be different from that of normal pregnant women. In the course of expanding of our studies, we found that lysoPLD activity toward endogenous substrates in sera from patients with preterm labor and pre-eclampsia was higher than that of women with normal pregnancy. The aim of the present study was to unmask components in blood circulation that are relevant for differences in serum lysoPLD activity between women with normal pregnancy and pathological pregnancy. In addition, we wanted to know whether lysoPLD activity in serum from pregnant women was actually due to ATX. Measurement of phosphocholine phosphatase, GPC:choline phosphodiesterase and lysoPLD activity in human serum
Materials and Methods

Materials
LysoPLD activity was routinely measured as follows, essentially as described previously (Tokumura et al., 2002a) . First, 0.1 ml aliquots of serum samples diluted with saline to 3.3-or 10-fold were incubated with 0.05 ml of 0.45 mM 18:2-LPC or 16:0-LPC dispersed in saline containing 0.25% fatty acid-free BSA, at 378C for 24 h. Secondly, 0.1 ml aliquots of the mixtures were withdrawn and mixed with 2.6 ml of 0.1 M Tris -HCl buffer (pH 8.5), 0.2 ml of 7.5 mM HPPA solution, 0.1 ml of choline oxidase solution (2 U/ml), 0.01 ml of horseradish peroxidase solution (300 U/ml). The released choline for 15 min at 378C was determined by measuring the intensity of fluorescence from the oxidation product of HPPA at an excitation wavelength of 320 nm and emission wavelength of 404 nm, essentially as described (Zaitsu and Ohkura, 1980) . The quantification of choline released from endogenous cholinecontaining substances in human serum was performed on 3.3-fold diluted serum and undiluted serum with and without mixing with 0.05 ml saline containing 0.25% BSA, respectively. In experiments on the dilution dependence of the choline-producing activity where 0.1 ml of undiluted, 3.3-, 10-, 33-and 100-fold diluted serum samples were incubated with 0.05 ml of 450 mM of exogenous LPC under our assay conditions, the ratio of endogenous LPC to exogenous LPC was estimated roughly to be 133:150, 40:150, 13:150, 4:150 and 1.3:150, respectively. Choline-releasing activities against 0.15 mM exogenously added GPC or p-choline were measured with 3.3-fold diluted serum samples for 24 and 6 h, respectively, as described for measurement of lysoPLD activity. The activity measured in the presence of exogenous p-choline was simply calculated from four times the measured value described above, and shown as nanomoles per milliliter per 24 h.
Quantification of p-choline and GPC
The level of p-choline in 0.02 ml of human serum was assessed by subtracting the level of choline released during its incubation without alkaline phosphatase (0.001 ml saline alone), from that released during its incubation with 0.001 ml of saline solution including alkaline phosphatase.
To the incubation mixture on a 96-well plate were added 0.02 ml of saline, 0.1 ml of 0.1 M Tris-HCl buffer (pH 8.5), 0.2 ml of 7.5 mM HPPA solution, 0.04 ml of horseradish peroxidase solution (2 U/ml) and 0.02 ml of choline oxidase solution (25 U/ml). Intensity of fluorescence from the assay mixture at an excitation wavelength of 320 nm and emission wavelength of 404 nm was successively measured in a microplate reader (Fluoroskan Ascent CF, Thermo Labosystems). The level of GPC in human serum was assessed in the presence of Ca 2þ at a final concentration of 10 mM by the same procedures described above, except that GPC:choline phosphodiesterase with a high activity was used instead of alkaline phosphatase. We confirmed that exogenously added GPC and p-choline at up to 50 nmol/ml was quantitatively degraded to choline under our assay conditions.
Analysis of molecular species of LPC
Quantification of individual LPC molecular species was performed by gas-liquid chromatography of fatty acid methyl esters derived from LPC purified by thin-layer chromatography (TLC) with the use of 17:0-LPC as an internal standard, by the essentially same method described previously (Tokumura et al., 2002b) . Serum (0.2 ml) was diluted to 2 ml with distilled water containing 0.2 g KCl, and lipids were extracted by the method of Bligh and Dyer (1959) after the addition of 17:0-LPC (5 nmol). The extract was then fractionated on a Whatman K6 TLC plate developed with a solvent system of chloroform-methanol -20% ammonium hydroxide (60:35:8, v/v) . Silica gel containing LPC was scraped from the plate, and LPC was extracted from the silica gel suspension in distilled water by the method of Bligh and Dyer (1959) . Recovered LPC was then converted to fatty acid methyl esters, and determined by GLC.
Precipitation of lysoPLD activity in human sera by incubating with anti-ATX antibody-coated beads and its recovery from the precipitated beads Anti-mouse ATX monoclonal antibody coupled to Sepharose 4B beads (2 mg/ml) was prepared as described previously (Tanaka et al., 2006) . Human sera (0.12 ml) were incubated with the anti-ATX-antibody beads (0.03 ml) for 2 h at 48C under shaking every 15 min, as reported previously (Tokumura et al., 2007) . After centrifugation (48C, 10 000g, 1 min), 0.1 ml aliquots were withdrawn for measuring the activity of lysoPLD against 18:2-LPC. In some experiments, the precipitated beads were immediately washed with 1 ml of saline, and then incubated with 0.15 ml of 100 mM glycine buffer (pH 2.5) at 48C for 30, 60 or 90 min to recover lysoPLD /ATX from the precipitated Sepharose beads. After adjusting pH of the supernatant to 6 -7, 0.1 ml aliquots were quickly withdrawn, and the choline-producing activity was measured. A remaining portion of supernatants and serum samples were subjected to western blot analysis, as described previously (Tokumura et al., 2007) .
Statistical analysis
Statistical comparison of the means of two groups was conducted with Fisher's PLSD multiple comparison test. P , 0.05 was considered significant.
Results
By quantifying LPA produced from radioactive LPC added to serum samples, we previously found that radioactive LPA was produced at a constant rate during incubation of human serum for 6 h at 378C, and that lysoPLD activity in human serum was progressively increased throughout pregnancy (Tokumura et al., 2002b) . In this investigation, however, we adapted the enzyme-linked determination for choline (Tokumura et al., 2002a) , but not LPA, released from exogenous LPC as a more convenient assay for serum lysoPLD activity, because of both a large number of samples and their limited volumes available. In our standard assay, 0.1 ml of diluted human serum was incubated with 0.05 ml of saline with 0.1% BSA and 0.45 mM 16:0-or 18:2-LPC, major saturated or polyunsaturated molecular species. Previously, we reported that LPA accumulated constantly when sera from pregnant and non-pregnant women were incubated at 378C (Tokumura et al., 2002b) . In addition, choline was produced at a same rate during 24 h in undiluted and diluted serum samples in the present study (data not shown). From these results, we chose 24-h incubation for subsequent experiments. First, we examined the dilution dependency of our assay procedure in the presence of exogenous 16:0-LPC at a final concentration of 0.15 mM, although variable amounts of endogenous LPC in differently diluted sera might interfere with the determination of the cholineproducing activity to some extent by an unknown mechanism. The choline-producing activity in the assay mixture was corrected with a dilution rate. The activity, expressed as nanomoles of choline produced in milliliter of undiluted serum for 24 h, increased with an increase in the dilution rate in typical cases of women with normal pregnancy, patients with preterm labor and patients with preeclampsia, as shown in Fig. 1A . The values for patients with pathological pregnancy were higher than those for women with normal pregnancy at different dilution factors. However, the values for 33-and 100-fold diluted samples were more variable than those of 3.3-and 10-fold diluted samples, while the former was higher than the latter. Furthermore, based on these preliminary results, we selected 3.3-and 10-fold diluted sera for the standard assay for choline-producing activity in the presence of exogenous LPC, but data on the activity in 10-fold diluted sera was included only in Fig. 6C . Fig. 1B shows typical results with three groups on dilution dependence of the serum choline-producing activity toward endogenous substrates. Considering the result, we selected undiluted sera for the standard assay for choline-producing activity toward endogenous substrates. Secondly, we examined whether lysoPLD activity of ATX is responsible for the choline-producing activity in sera from pregnant women.
For this purpose, we tested whether the choline-producing activity is reduced by treatment of human serum with beads coated by anti-ATX/lysoPLD antibody. As shown in Fig. 2A , a large portion of the activity toward exogenous 16:0-LPC in 3.3-fold diluted sera Elevated serum LPA production in abnormal pregnancy from different patient groups was inhibited by their treatment with the immuno-adsorbent beads, supporting that the choline production from exogenous LPC was largely due to lysoPLD activity of ATX. Similarly, the large portion of choline-producing activity of undiluted sera in the absence of exogenous LPC was precipitated with beads coating anti-ATX antibody, indicating that the predominant endogenous substrate was LPC. In order to confirm whether the observed decrease in choline-producing activity was actually due to immunoprecipitation of ATX in serum samples with anti-ATX antibody beads, we tried to recover intact ATX from the precipitated beads by incubating the precipitated beads in 100 mM glycine buffer, and recovered choline-producing activity was measured. Unexpectedly, only low recovery was attained for samples from a woman with normal pregnancy (Fig. 2B) . Similar, but moderate, recoveries of choline-producing activity were observed for 3.3-fold diluted sera from patients with abnormal pregnancy (Fig. 2B) . Western blot analysis of supernatants after incubation of precipitated anti-ATX antibody beads in 100 mM glycine buffer detected a faint immunostained band that migrated similarly with recombinant ATX in electrophoresis, while recovered amounts of immunostained proteins were much lower in serum samples before treatment with anti-ATX antibody-Sepharose beads (Fig. 2C) . We detected dense bands with a lower molecular mass in these three supernatant samples under reducing conditions (Fig. 2C) . Thus, the low recoveries of the choline-producing activity shown in Fig. 2B may be due to rapid degradation of ATX in 100 mM glycine buffer to inactive degradation products, although we provide no information on molecular mechanisms concerning the unstable property of ATX purified by the immunoprecipitation. We could not exclude the possibility that the immunostained band with lower molecular weight was due to a contaminating protein bound to the anti-ATX antibody beads. Alternatively, the loss of lysoPLD activity might be denaturation of ATX in the glycine buffer (pH 2.5). It should be mentioned that purified ATX protein was unstable in standard conditions (Giganti et al., 2008) . Considering these results altogether, we still suggest that the choline-producing activity precipitated with the beads was actually due to ATX.
Quite high and moderate choline-producing activities toward exogenous p-choline and GPC (0.15 mM) were detected in sera samples from the four patient groups, while the measured activity would include choline production from endogenous LPC (about 0.04 mM) (Fig. 3 ). Significant differences were observed between the normal group and preterm labor group (activities toward p-choline and GPC) or moderate pre-eclampsia group (activity toward GPC). We measured serum levels of p-choline and GPC by determining the choline release by 3.3-fold diluted serum samples from three patient groups in the presence or absence of exogenous alkaline phosphatase and GPC:choline phosphodiesterase. However, we detected no significant differences in the choline levels of sera incubated between with and without exogenous alkaline phosphatase or GPC:choline phosphodiesterase, indicating that endogenous serum levels of p-choline and GPC in these serum samples would be less than 1 mM (data not shown). Possible sources of production of p-choline and GPC in serum are hydrolysis of LPC by lysophospholipase A-like activity and hydrolysis of phosphatidylcholine, sphingomyelin and LPC by phospholipase C-like activity, respectively. Because human serum is believed to have essentially no phospholipase D activity toward phosphatidylcholine and sphingomyelin (Huang et al., 1990; Van Meeteren et al., 2004) , we did not measure such activity.
Thirdly, we measured the levels of various LPCs in fresh sera samples from control, pre-eclamptic and preterm labor groups. However, differences of mean values of individual LPC levels among sera from three patient groups did not reach statistical significance (Fig. 4) .
Fourthly, the choline-producing activities that are due mainly to lysoPLD activity of ATX in the 3.3-fold diluted serum samples from four patient groups were compared after their incubation with exogenous 16:0-LPC or 18:2-LPC at the final concentration of 0.15 mM (Fig. 5A) . In these groups, except for the patients with preterm labor, the mean values of sera incubated with 18:2-LPC was significantly higher than those with 16:0-LPC. Consistent with our earlier preliminary results (Tokumura et al., 2002a) , the serum lysoPLD activity toward 16:0-LPC in patients with preterm labor (30.1 + 0.8 gestational weeks; n ¼ 21) was significantly higher than those in women with normal pregnancy (35.8 + 0.7 gestational weeks; n ¼ 25), whereas there were no differences in the activities for 18:2-LPCs among the four groups. In order to compare the results of women with normal and abnormal pregnancy having a similar range of gestational age, we divided women with normal pregnancy into two subgroups (31.4 + 0.24 gestational weeks, n ¼ 10) and 39.1 + 0.26 gestational weeks, n ¼ 15), and the results of the normal subgroups were compared with those of patients with abnormal pregnancy. Statistically significant differences were observed in Figure 1 Dilution dependency of choline-producing activity of sera from patients with normal and abnormal pregnancy.
In the presence (A) and absence (B) of 0.15 mM exogenous 16:0-LPC, choline-producing activity was measured for undiluted (100 ml serum) and 3.3-(33 ml serum þ 67 ml saline), 10 (10 ml serum þ 90 ml saline)-, 30 (3.3 ml serum þ 96.7 ml saline) and 100 (1 ml serum þ 99 ml saline)-fold diluted serum from a woman with normal pregnancy (field circle), a patient with severe pre-eclampsia (open circle) and a patient with preterm labor (open triangle). Values are the means of triplicate determinations.
both cases. The ratios of lysoPLD activity toward 18:2-LPC to that toward 16:0-LPC are shown in Fig. 5B . The mean value of ratio for patients with preterm labor was significantly less than those for women with normal pregnancy and patients with severe pre-eclampsia.
We compared the choline-producing activity toward endogenous substrates in undiluted and 3.3-fold diluted sera. Surprisingly, the mean values for undiluted sera from patients with abnormal pregnancy were higher than that for women with normal pregnancy, as shown in Fig. 6A . Whereas only low levels of choline were detected in most 24-h incubated serum samples of normal pregnant women, the mean value for preterm labor patients was the highest followed by that for patients with severe pre-eclampsia. The serum level of choline accumulated in the 24-h incubated sera of pre-eclamptic Figure 2 Characterization choline-producing activities in sera from pregnant women with anti-ATX antibodies.
(A) Inhibition by immunoprecipitation of choline-producing activities of undiluted and 3.3-fold diluted sera from a woman with normal pregnancy (white bars), a patient with preterm labor (black bars) and a patient with pre-eclampsia (gray bars) in the presence or absence of exogenous 16:0-LPC at 0.15 mM were examined, respectively. Results are the mean values + SD. of triplicate determinations. (B) After incubation of 3.3-fold diluted sera from women with normal pregnancy (white bars, n ¼ 4), preterm labor (black bars, n ¼ 2) and severe pre-eclampsia (gray bars, n ¼ 2) with anti-mouse ATX antibody coupled to Sepharose 4B beads, the diluted serum was separated from the beads, and its remaining choline-producing activity was measured. The precipitated beads were immediately incubated with 100 mM glycine buffer at 48C for 1 h, and the choline-producing activity of the supernatant was measured. Percentages of the activity recovered in 100 mM glycine buffer to the decreased activity by immunoprecipitation of the diluted serum were calculated. (C) Western blot analysis was performed with serum sample from a woman with normal pregnancy (N), a patient with pre-eclampsia (P-1) and a patient with preterm-labor (P-2) at a final dilution rate of 15-fold. The 3.3-fold diluted sera were incubated with anti-ATX antibody-Sepharose beads. Immediately, the beads were washed and incubated in 100 mM glycine buffer. Proteins in the recovered supernatants were subjected to western blot analysis together with recombinant human ATX (Rec. ATX). The final dilution rate for the supernatants was adjusted to 3-fold.
Elevated serum LPA production in abnormal pregnancy women was high, but more variable compared with that of patient group with preterm labor. However, there was no significant difference in the choline-producing activity of 3.3-fold diluted serum samples in the absence of exogenous LPC (Fig. 6B) . We found some association between the ratios of activity in 10-fold diluted sera to that in 3.3-fold diluted sera toward 16:0-LPC (Fig. 6C) or 18:2-LPC (data not shown) and choline-producing activity from endogenous substrates in undiluted sera. Sera from patients with preterm labor had higher choline-producing activity toward endogenous substrate and lower dilution dependency of choline-producing activity toward exogenous LPC. The reverse was true for control patients. Values for pre-eclamptic patients were more variable, but had a tendency with higher activity for endogenous substrate and lower ratios of activity (10-fold diluted sera/3.3-fold diluted sera). Higher ratios of choline-producing activity in 10-fold diluted serum to that in 3.3-fold diluted serum in most of women under normal pregnancy and in some patients with pre-eclampsia may reflect greater recovery of inhibition of the enzyme by sequential dilutions of the serum sample, indicating existence of more inhibitory substances in the serum sample. 
Discussion
In this study, we provided several lines of evidence that the lysoPLD activity of ATX in human serum is predominantly associated with the choline-producing activity toward endogenous substrates and exogenous LPC under both normal and abnormal pregnancy. We found no significant differences among lysoPLD activities in the presence of exogenous 18:2-LPC, at a relatively high concentration (0.15 mM), among women with normal pregnancy and women with preterm labor and pre-eclampsia, indicating that the serum level of ATX would be similar among the three patient groups. However, we found significant differences in lysoPLD activity in the presence of 0.15 mM 16:0-LPC between patients with preterm labor and women with normal pregnancy. Because our results showed no significant differences among serum levels of LPC, a predominant endogenous substrate for serum lysoPLD, availability of 16:0-LPC, but not of 18:2-LPC, would be elevated in sera from patients with preterm labor. But, unfortunately, the molecular basis of why the availability of 16:0-LPC to ATX was elevated in sera from patients with preterm labor remains unclear. The distribution of 16:0-LPC among various protein-or lipoprotein-bound forms in patients with abnormal pregnancy might be distinct from that in sera from women under normal pregnancy.
In the current study, the lysoPLD activity in normally pregnant patients was found to be highly dependent on the dilution rate of serum; when increasing the dilution rate, the lysoPLD activity expressed as choline per milliliter of original serum volume was increased. This might be explained by considering that a potent inhibitory effect of unknown serum factor on lysoPLD activity was greatly weakened to a larger extent than the decrease in the lysoPLD activity due to dilution of ATX itself, when the serum was diluted in a stepwise manner. Stronger inhibition due to more inhibitors may occur in undiluted sera from patients with normal pregnancy than in undiluted sera from patients with abnormal pregnancy, because significantly higher lysoPLD activity toward endogenous substrates for the latter was observed compared with that for the former. The serum with higher activity for endogenous substrates gave a result with lower dilution dependency of lysoPLD activity toward exogenous LPC (10-fold diluted versus 3.3-fold diluted serum), supporting this hypothesis that the strong inhibition of serum lysoPLD activity observed under normal pregnancy may be weakened or released by an unknown mechanism under abnormal pregnancy. In this context, Figure 5 Comparison of choline-producing activities of sera from women during normal and abnormal pregnancy. it should be mentioned that group II secretory phospholipase A 2 levels in patients with severe pre-eclampsia has been reported to be significantly higher than those of mild pre-eclamptic and control patient groups (Lim et al., 1995) . Like the case of pre-eclamptic patients (Pulkkinen et al., 1993) , the activity of group II secretory phospholipase A 2 in serum of women with preterm labor is significantly elevated compared with those of sera from pregnant women with term labor and non-pregnant women (Koyama et al., 2000) . Thus, secretory phospholipase A 2 may be a common factor that is associated with increased lysoPLD activity in sera under unusual pregnancy through the supply of lysophospholipids, including LPC that are easily accessible to hydrolysis by lysoPLD. Thus, LPC produced by secretory phospholipase A 2 may be utilized to a larger extent to serum lysoPLD. Alternatively, free fatty acid produced by secretory phospholipase Figure 6 Relationship of between choline-producing activity toward endogenous substrates and relative choline-producing activity of two diluted serum samples toward exogenous 16:0-LPC in sera from different groups.
(A) and (B) Choline production was measured during 24-h incubation of undiluted and 3.3-fold diluted sera, respectively, in the absence of exogenous LPC. a Significant difference against normal group, b Significant difference against moderate pre-eclampsia group. (C) Choline-producing activity toward the endogenous substrate in undiluted serum was plotted against the ratio of choline-producing activity toward exogenous 16:0-LPC in 10-fold diluted serum to that in 3.3-fold diluted serum from normal pregnant women, patients with preterm labor and patients with mild (open symbol) and severe (closed symbol) pre-eclampsia.
A 2 may increase the apparent availability of endogenous LPC to lysoPLD by competitively binding to lipid-sequestering proteins (albumin, a1-acid protein, lipoproteins) in a competitive manner with the lysoPLD substrate LPC. Concentrations of non-esterified fatty acids are elevated in plasma from women with severe preeclampsia compared with those from the control group (Vigne et al., 1997) . Actually, higher molar ratios of non-esterified fatty acid to albumin in sera from pre-eclamptic women has been shown to correlate with endothelial injury (Endresen et al., 1992) and increased hydrolytic activity against LPC has been reported to be involved in the elevated release of free fatty acid (Endresen et al., 1993) . More works are needed to identify the sources and mechanisms for elevated productions of LPA and choline in incubated sera from patients with abnormal pregnancy. Similarly, attempts should be made to understand the contribution of elevated production of LPA in induction of pre-eclamptic syndrom(s) and the syndrome leading to preterm labor in maternal circulation.
